HYFT vs IBO

MindWalk Holdings Corp. vs Impact BioMedical, Inc. — Valuation Comparison 2026

HYFT

Pharmaceutical Preparations
MindWalk Holdings Corp.
Quality
1.7
out of 10
Value Trap
Price
$1.76
Last close
Models
8/13
Active
VS

IBO

Pharmaceutical Preparations
Impact BioMedical, Inc.
Quality
4.4
out of 10
Value Trap
20
SAFE
Price
$0.52
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType HYFT Fair ValueHYFT Upside IBO Fair ValueIBO Upside
Bayesian DCF Intrinsic $0.42 -75.9% $0.12 -76.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.12 -90.6% $0.02 -95.2%
PWERM Option-Based $1.40 -20.7% $0.49 -6.1%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for HYFT vs IBO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

HYFT vs IBO — Which Stock Is More Undervalued?

IBO scores higher with a 4.4/10 quality rating vs HYFT's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing MindWalk Holdings Corp. (HYFT) and Impact BioMedical, Inc. (IBO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

HYFT currently trades at $1.76 with a QOC of 1.7/10, while IBO trades at $0.52 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).